Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS).
ARDS
Blood purification
Critically ill COVID-19
Cytokine storm
Plasmapheresis
Journal
Pulmonology
ISSN: 2531-0437
Titre abrégé: Pulmonology
Pays: Spain
ID NLM: 101723786
Informations de publication
Date de publication:
Historique:
received:
22
06
2020
revised:
28
10
2020
accepted:
29
10
2020
pubmed:
29
12
2020
medline:
15
12
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
In December 2019, pneumonia associated with a novel coronavirus (COVID-19) was reported in Wuhan, China. Acute respiratory distress syndrome (ARDS) is the most frequently observed complication in COVID-19 patients with high mortality rates. To observe the clinical effect of plasmapheresis on excessive inflammatory reaction and immune features in patients with severe COVID-19 at risk of ARDS. In this single-center study, we included 15 confirmed cases of COVID-19 at Masih Daneshvari Hospital, in March 2020 in Tehran, Iran. COVID-19 cases were confirmed by RT-PCR and CT imaging according to WHO guidelines. Plasmapheresis was performed to alleviate cytokine-induced ARDS. The improvement in oxygen delivery (PaO Inflammatory cytokine levels (TNF-α, IL-6), and acute phase reaction proteins including ferritin and CRP were high before plasmapheresis. After plasmapheresis, the levels of PaO Our data suggests that plasmapheresis improves systemic cytokine and immune responses in patients with severe COVID-19 who do not undergo IMV. Further controlled studies are required to explore the efficacy of plasmapheresis treatment in patients with COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
In December 2019, pneumonia associated with a novel coronavirus (COVID-19) was reported in Wuhan, China. Acute respiratory distress syndrome (ARDS) is the most frequently observed complication in COVID-19 patients with high mortality rates.
OBJECTIVE OF STUDY
OBJECTIVE
To observe the clinical effect of plasmapheresis on excessive inflammatory reaction and immune features in patients with severe COVID-19 at risk of ARDS.
MATERIALS AND METHODS
METHODS
In this single-center study, we included 15 confirmed cases of COVID-19 at Masih Daneshvari Hospital, in March 2020 in Tehran, Iran. COVID-19 cases were confirmed by RT-PCR and CT imaging according to WHO guidelines. Plasmapheresis was performed to alleviate cytokine-induced ARDS. The improvement in oxygen delivery (PaO
RESULTS
RESULTS
Inflammatory cytokine levels (TNF-α, IL-6), and acute phase reaction proteins including ferritin and CRP were high before plasmapheresis. After plasmapheresis, the levels of PaO
CONCLUSION
CONCLUSIONS
Our data suggests that plasmapheresis improves systemic cytokine and immune responses in patients with severe COVID-19 who do not undergo IMV. Further controlled studies are required to explore the efficacy of plasmapheresis treatment in patients with COVID-19.
Identifiants
pubmed: 33358260
pii: S2531-0437(20)30254-3
doi: 10.1016/j.pulmoe.2020.10.017
pmc: PMC7834188
pii:
doi:
Substances chimiques
Cytokines
0
Interleukin-6
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
486-492Informations de copyright
Copyright © 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.
Références
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet Digit Health. 2020 Jun;2(6):e286-e287
pubmed: 32363333
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
Lancet Infect Dis. 2020 Jul;20(7):773
pubmed: 32171390
Arthritis Rheum. 2006 Aug;54(8):2568-76
pubmed: 16868979
J Pathol. 2015 Jan;235(2):185-95
pubmed: 25270030
Nature. 2019 Sep;573(7775):546-552
pubmed: 31461748
Blood Purif. 2019;47 Suppl 3:1-7
pubmed: 30982028
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
J Inflamm (Lond). 2014 Aug 05;11:21
pubmed: 25110464
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Blood Purif. 2019;48(4):382-384
pubmed: 31357202
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
J Clin Apher. 1996;11(1):10-3
pubmed: 8722715
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Ann Intensive Care. 2019 May 14;9(1):56
pubmed: 31089920
Curr Probl Cardiol. 2020 Aug;45(8):100618
pubmed: 32439197
Transfusion. 2018 Feb;58 Suppl 1:580-589
pubmed: 29443413
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Lancet. 1993 Mar 13;341(8846):643-7
pubmed: 8095568
Engineering (Beijing). 2021 Jan;7(1):11-13
pubmed: 32292628
Hematol Transfus Cell Ther. 2020 Apr - Jun;42(2):125-128
pubmed: 31387798
Ann Transl Med. 2016 Sep;4(18):341
pubmed: 27761445
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
Eur J Haematol. 2015 Apr;94(4):368-73
pubmed: 24813235
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
J Trop Med. 2018 Dec 2;2018:4520185
pubmed: 30631369
Clin Immunol. 2020 May;214:108408
pubmed: 32247038
Res Commun Mol Pathol Pharmacol. 2001 Jul;109(1-2):65-72
pubmed: 11458986
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Chronic Dis Transl Med. 2020 Apr 28;6(2):106-114
pubmed: 32346492